Nachrichten zur Roivant Sciences Ltd. Aktie

Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses

…

Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript

…

Roivant Sciences Ltd. 2024 Q1 - Results - Earnings Call Presentation

…

Roivant Sciences: Executing On Huge Buyback Program With More To Come

…

Roivant Sciences Ltd. (ROIV) Q4 2023 Earnings Call Transcript

…

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 8% and 10.86%, respectively, for the quarter ended March 2024.…

Moderna: Lizenzgebühren an Arbutus im Fokus - Aktienanalyse

New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Jefferies & Co: Michael Yee, Analyst von Jefferies & Co, rät in einer aktuellen Aktienanalyse…

Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success

…

Roivant Sciences stock target raised to $16 by Goldman Sachs By Investing.com

Roivant Sciences stock target raised to $16 by Goldman Sachs…

Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript

…

Roivant Sciences Q3 2024 Earnings Preview

…

Roivant Sciences: Why Its Vant Biotech Model Is A Buy

…

Roivant Sciences gets disappointing lupus drug results in Phase 2 study

Roivant Sciences stock moved lower on Monday after the biopharmaceutical company announced that its lupus therapeutic oral brepocitinib failed to…

: Roivant Sciences shares drop as lupus treatment misses trial goal

Roivant Sciences Ltd. shares ROIV fell 3% premarket on Monday after the company said the experimental treatment brepocitinib failed to…

Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript

…

Roivant Sciences Ltd. 2023 Q2 - Results - Earnings Call Presentation

…

Roivant cash-flush after $7.25B Telavant sale to Roche as it reports mixed 3Q

Roivant Sciences has reported a third-quarter earnings miss but revenue that topped analysts’ expectations, sending its shares higher in Monday…

Roivant cash-flush after $7.15B Telavant sale to Roche as it reports mixed 3Q

Roivant Sciences has reported a third-quarter earnings miss but revenue that topped analysts’ expectations, sending its shares higher in Monday…

Roivant Sciences: Risk-Transforming Deal Met With Crickets

…

Its Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy

The markets dour reaction to Roivant Sciences latest deal doesnt add up.…

Its Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy @themotleyfool #stocks $ROIV $PFE $RHHBY $XBI

The markets dour reaction to Roivant Sciences latest deal doesnt add up.…

Biggest stock movers today: Crypto-focused stocks, Roivant Sciences and more

…

Roche kauft für bis zur 7,25 Mrd USD Darm-Spezialist von Roivant Sciences und Pfizer

DJ Roche kauft für bis zur 7,25 Mrd USD Darm-Spezialist von Roivant Sciences und Pfizer Von Adria Calatayud BASEL (Dow…

Roche to buy Telavant from Roivant Sciences, Pfizer in $7.25 billion deal

Roche to buy Telavant from Roivant Sciences, Pfizer in $7.25 billion deal…

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

BASEL, Switzerland and LONDON and NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today…

[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant

Basel, 23 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive agreement to…

Roivant Sciences COO Eric Venker sells ~440.8K

…

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to…

Roivant Sciences files for $1.5B mixed shelf

…

NASDAQ Composite Index-Titel Roivant Sciences-Aktie: So viel Gewinn hätte ein frühes Investment in Roivant Sciences abgeworfen

Die Roivant Sciences-Aktie wurde heute vor 1 Jahr via Börse NAS wochenend-bedingt nicht gehandelt. Am Handelstag zuvor stand das Roivant…

Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal

Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings…

dpa-AFX ProFeed